SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Saqib Islam Sells 10,672 Shares

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Saqib Islam sold 10,672 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $59.92, for a total value of $639,466.24. Following the transaction, the chief executive officer now directly owns 1,063,953 shares in the company, valued at approximately $63,752,063.76. This represents a 0.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Saqib Islam also recently made the following trade(s):

• On Monday, February 10th, Saqib Islam sold 48,000 shares of SpringWorks Therapeutics stock. The stock was sold at an average price of $53.30, for a total value of $2,558,400.00.

SpringWorks Therapeutics Trading Down 1.0 %

Shares of SWTX opened at $55.73 on Thursday. SpringWorks Therapeutics, Inc. has a twelve month low of $28.21 and a twelve month high of $60.00. The stock’s 50 day moving average is $40.27 and its two-hundred day moving average is $37.31. The firm has a market capitalization of $4.15 billion, a PE ratio of -14.36 and a beta of 0.81.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Guggenheim lowered their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $74.00 price target on shares of SpringWorks Therapeutics in a report on Wednesday, February 12th. Wedbush reissued an “outperform” rating and set a $77.00 price target on shares of SpringWorks Therapeutics in a report on Monday, February 10th. Finally, Evercore ISI raised their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $70.83.

Institutional Investors Weigh In On SpringWorks Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SWTX. Huntington National Bank boosted its holdings in SpringWorks Therapeutics by 38.2% in the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock valued at $25,000 after purchasing an additional 192 shares in the last quarter. AlphaQuest LLC boosted its stake in shares of SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after acquiring an additional 414 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of SpringWorks Therapeutics during the 4th quarter worth approximately $45,000. State of Wyoming boosted its stake in shares of SpringWorks Therapeutics by 39.5% during the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock worth $55,000 after acquiring an additional 433 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of SpringWorks Therapeutics during the 4th quarter worth approximately $56,000.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.